Trial Profile
Cost-effectiveness analysis of different protease inhibitors-based strategies in the treatment of naive patients with genotype 1 chronic hepatitis C (G1-CHC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ADVANCE; SPRINT-2
- Sponsors Merck Sharp & Dohme
- 29 Jan 2013 New trial record